Original and generic drugs: what does the clinician need to know?

Close metadata

Recommended articles:

Efficacy of Mexidol in combination with cerebral revascularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74

Cognitive impairment in patients with arterial hypertension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48

The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. S.S. Korsakov Journal of Neurology and Psychiatry. 2006;(12-2):47-54

Treatment of patients with ishemic stroke in the vertebral-basilar system in acute period: experience of using the neuroprotective drug Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):78-84

Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):42-51

Results of a cohort single-center randomized study of the modulating effect of the drug Mexidol in the rehabilitation of patients who suffered acute cerebral insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):108-117

Possibilities of using cytoprotectors in complex therapy of chronic coronary heart disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):410-419

The role of mitochondrial dysfunction in the stabilization of the glaucomatous process. Russian Annals of Ophthalmology. 2024;(4):49-58

Ethylmethylhydroxypyridine succinate enhances analgesic effect of cyclooxygenase inhibitors in rats with postoperative hyperalgesia. Russian Journal of Pain. 2024;(3):5-11

The effect of ethylmethylhydroxypyridine succinate on the parameters of chronic neuroinflammation and plastic processes in the brain of old rats during course of dexamethasone administration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):115-121

In the review article modern approaches to testing and registration of generic drugs are discussed. The article presents the history of the formation of the methodology for testing generic drugs and the current legislation of the Russian Federation. The stages of confirmation of equivalence of original and generic drugs are described: pharmaceutical equivalence, bioequivalence and therapeutic equivalence. The methods of assessing bioequivalence — as the main research in the registration of generic drugs — are discussed in detail. Using the example of the original neuroprotector — Mexidol (ethylmethylhydroxypyridine succinate) and its generics, it is described how legislative acts are implemented in practice. It is concluded that not all generic drugs are interchangeable for the original drug.

Keywords:

original and generics drugs

ethylmethylhydroxypyridine succinate

mexidol

Authors:

Shchulkin A.V.

Pavlov Ryazan State Medical University

Filimonova A.A.

Ryazan State Medical University

Received:

20.09.2021

Accepted:

30.09.2021

List of references:

Gupta R, Shah ND, Ross JS. Generic Drugs in the United States: Policies to Address Pricing and Competition. Clin Pharmacol Ther. 2019;105(2):329-337. https://doi.org/10.1002/cpt.1314
Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858-871. https://doi.org/10.1001/jama.2016.11237
Yu LX, Li BV. FDA Bioequivalence Standards. aapspress/Springer; 2014.
Lindenbaum J, Mellow MH, Blackstone MO, Butler VP Jr. Variation in biologic availability of digoxin from four preparations. N Engl J Med. 1971;285:1344-1347. https://doi.org/10.1056/NEJM197112092852403
Wagner JG, Christensen M, Sakmar E, et al. Equivalence lack in digoxin plasma levels. JAMA. 1973;224:199-204.
Skelly JP. Bioavailability and bioequivalence. J Clin Pharmacol. 1976;16:539-545. https://doi.org/10.1177/009127007601601013
Federal’nyj zakon Rossijskoj Federacii №475 ot 27 dekabrja 2019 g. «O vnesenii izmenenij v Federal’nyj zakon «Ob obrashhenii lekarstvennyh sredstv» i Federal’nyj zakon «O vnesenii izmenenij v Federal’nyj zakon «Ob obrashhenii lekarstvennyh sredstv». (In Russ.). https://rg.ru/2019/12/31/a1804425-dok.html
Teoreticheskie i prakticheskie osnovy provedenija issledovanij vosproizvedennyh lekarstvennyh preparatov: monografija. Pod red. Hohlova A.L. OOO Fotolajf; 2017. (In Russ.).
«Ob utverzhdenii Pravil provedenija issledovanij biojekvivalentnosti lekarstvennyh preparatov v ramkah Evrazijskogo jekonomicheskogo sojuza». (In Russ.). https://docs.eaeunion.org/docs/ru-ru/01411942/cncd_21112016_85
O vnesenii izmenenij v Pravila provedenija issledovanij biojekvivalentnosti lekarstvennyh preparatov v ramkah v Evrazijskogo ekonomicheskogo sojuza. (In Russ.). https://docs.eaeunion.org/docs/ru-ru/01427352/err_11092020_67
Draft Guidance. Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA Guidance for Industry. August 2021. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). https://www.fda.gov/media/87219/download
Hauschke D, Steinijans, Pigeot I. Bioequivalence studies in drug development. Methods and applications. Wiley; 2007.
Anderson S, Hauck WW Consideration of individual bioequivalence. J Pharmacokinet Biopharm. 1990;18:259-273. https://doi.org/10.1007/BF01062202
Hauck WW, Anderson S. Measuring switchability and prescribability: when is average bioequivalence sufficient? J Pharmacokinet Biopharm. 1994;22:551-556. https://doi.org/10.1007/BF02353794
Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420. https://doi.org/10.1023/A:1016212804288
Federal’nyj zakon Rossijskoj Federacii №429 ot 22 dekabrja 2014 g. «O vnesenii izmenenij v Federal’nyj zakon «Ob obrashhenii lekarstvennyh sredstv». The link is active on 11.09.2021. (In Russ.). https://rg.ru/2014/12/26/lekarstva-dok.html
Gosudarstvennyj reestr lekarstvennyh sredstv. The link is active on August 25, 2021. https://grls.rosminzdrav.ru/Default.aspx
Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90. (In Russ.).
Schulkin AV. Mexidol: modern aspects of the pharmacokinetics and pharmacodynamics. Farmateka. 2016;4:65-71. (In Russ.).
Skvortsova VI, Stakhovskaya LV, Nartsissov YaR, et al. Randomizirovannoe dvoinoe slepoe platsebo-kontroliruemoe issledovanie effektivnosti i bezopasnosti meksidola v kompleksnoi terapii ishemicheskogo insul’ta v ostrom periode. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Pril. Insul’t). 2006;18:47-54. (In Russ.).
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117:3(2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Klinicheskie rekomendacii. Ishemicheskij insul’t i tranzitornaja ishemicheskaja ataka u vzroslyh. 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/171_2
Gil’deeva GN. Formirovanie mezhdisciplinarnogo podhoda k standartizacii i kontrolju kachestva vosproizvedennyh lekarstvennyh sredstv i prekvalifikacionnoj jekspertize lekarstvennyh preparatov: Dis. ... d-ra farm. nauk. M. 2017. (In Russ.). https://www.volgmed.ru/uploads/dsovet/thesis/2-766-gildeeva_geliya_nyazyfovna.pdf
Sravnitel’noe izuchenie biojekvivalentnosti lekarstvennyh preparatov Nejroks tabletki, pokrytye plenochnoj obolochkoj 125 mg, proizvodstva AO «IIHR», Rossija i Meksidol tabletki, pokrytye plenochnoj obolochkoj 125 mg, proizvodstva ZAO «ZiO-Zdorov’e», Rossija. (In Russ.). https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=29f8848a-4818-451f-b7d1-e0674c5d6372&CIPermGUID=13F402EE-6DC1-4A3D-9D76-7E1CB21B5557
Sravnitel’noe izuchenie biojekvivalentnosti lekarstvennyh preparatov Metostabil, tabletki, pokrytye plenochnoj obolochkoj, 125 mg, proizvodstva OOO «Ozon», Rossija i Meksidol, tabletki, pokrytye obolochkoj, 125 mg, proizvodstva «ZiO-Zdorov’e», Rossija. The link is active on September 11, 2021. (In Russ.). https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=d867af1a-7fd1-4d91-a9b4-f0219325197f&CIPermGUID=C8E47357-82AA-4A48-8AEE-8A078D5CF62B
Shchul’kin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39. (In Russ.).
Kosolapov VA, Spasov AA, Anisimova V. A Study of antiradical activity of new compounds by chemiluminescence. Biomeditsinskaya Khimiya. 2005;51(3):287-294. Accessed October 16, 2018. (In Russ.).
Kirova YuI, Germanova EL. New aspects of the energy-tropic action of mexidol. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya. 2018;62(4):42-46. (In Russ.). https://doi.org/10.25557/0031-2991.2018.04.36-40
Rekomendacija №25 ot 2 sentjabrja 2019 g. «O Rukovodstve po doklinicheskoj i klinicheskoj razrabotke kombinirovannyh lekarstvennyh preparatov». The link is active on 11.09.21. (In Russ.). https://docs.eaeunion.org/docs/ru-ru/01422928/clcr_05092019_25

Close metadata